Roche disclosed interim adjuvant data showing its oral selective estrogen receptor degrader (SERD) reduced the risk of invasive disease recurrence or death by about 30% versus standard of care. The company presented the data in an interim analysis at SABCS and in a Phase 3 program update, naming giredestrant as the agent linked to the effect. The datasets reported include time‑to‑event measures that regulators and payers track for adjuvant approvals and reimbursement discussions. Key actors: Roche, investigators presenting at the San Antonio Breast Cancer Symposium (SABCS). The finding is based on a registrational adjuvant trial with invasive disease recurrence or death as the primary endpoint. Clarification: An adjuvant trial tests a therapy given after primary treatment (surgery) to reduce the risk of cancer returning.